Page 3,599«..1020..3,5983,5993,6003,601..3,6103,620..»

MEDIPOST America clears Phase 1/2 IND for the U.S …

Posted: Published on September 18th, 2014

ROCKVILLE, Md.--(BUSINESS WIRE)--MEDIPOST America Inc. (CEO: Dr. Antonio Lee) today announced the US FDA approval of Phase 1/2 clinical trial for PNEUMOSTEM. The Phase 1/2 trial will assess the safety and efficacy of PNEUMOSTEM on prematurely born infants who will be at high-risk of developing Bronchopulmonary Dysplasia (BPD). PNEUMOSTEM is made from allogeneic human Umbilical Cord Blood-derived Mesenchymal Stem Cells (hUCB-MSCs), and is expected to have effect on regenerating the lung tissue and improving inflammatory responses in premature infants. BPD is the leading cause of mortality and severe complications in premature infants and currently no therapy or approved drug exists. Hence, the PNEUMOSTEM trial is expected to draw global attention in the field of neonatal medicine. PNEUMOSTEM received Orphan Drug designation in Korea by the Ministry of Food and Drug Safety (MFDS) and the Phase 2 study in Korea is 80% complete. The US FDA also granted Orphan Drug designation for PNEUMOSTEM, demonstrating its medical value and commercial potential. MEDIPOST America will move quickly to commence the PNEUMOSTEM trial in the U.S. while continuing the licensing and technology transfer negotiations with multinational pharmaceutical companies. The clinical trial approval of PNEUMOSTEM by the US FDA which implements strict regulations on medicinal … Continue reading

Posted in FDA Stem Cell Trials | Comments Off on MEDIPOST America clears Phase 1/2 IND for the U.S …

First-Ever Human Trial Of An Induced Pluripotent Stem Cell …

Posted: Published on September 18th, 2014

A Japanese patient with severe eye disease is set to become the first person to be treated with induced pluripotent stem cells, Nature News reports. Cells of this type have been considered promising for future treatments since their creation eight years ago, which was itself a milestone. Thishuman test is set to be a historic moment in biotechnology. It's also an anxious one. Stem cell therapies carry the risk of creating tumors, although Nature News reports the scientists in charge of the Japanese trial found their treatment did not cause tumors in mice and monkeys. In addition, there might be other risks to the treatment that scientists aren't yet aware of; stem cell therapies of all types are only just being tried in humans. Induced pluripotent stem cells are special because they're not made from embryos. Instead, they come from harvesting skin cells from people, then treating those cells with genes that reverse the cell's life stage back to its stem cell state. That means scientists are able to make induced pluripotent stem cells from cells taken from a patient's own body. The resulting cells should be well matched to the patient's own genetics, although it's possible the "induction" part … Continue reading

Posted in Stem Cell Human Trials | Comments Off on First-Ever Human Trial Of An Induced Pluripotent Stem Cell …

World Breakthrough: A New Molecule Allows for an Increase in Stem Cell Transplants

Posted: Published on September 18th, 2014

Contact Information Available for logged-in reporters only Newswise Investigators from the Institute for Research in Immunology and Cancer (IRIC) at the Universit de Montral have just published, in the prestigious magazine Science, the announcement of the discovery of a new molecule, the first of its kind, which allows for the multiplication of stem cells in a unit of cord blood. Umbilical cord stem cells are used for transplants aimed at curing a number of blood-related diseases, including leukemia, myeloma and lymphoma. For many patients this therapy comprises a treatment of last resort. Directed by Dr. Guy Sauvageau, principal investigator at IRIC and hematologist at the Maisonneuve-Rosemont Hospital, this world breakthrough has the potential to multiply by 10 the number of cord blood units available for a transplant in humans. In addition, it will considerably reduce the complications associated with stem cell transplantation. And it will be particularly useful for non-Caucasian patients for whom compatible donors are difficult to identify. A clinical study using this molecule, named UM171 in honor of the Universit de Montral, and a new type of bioreactor developed for stem culture in collaboration with the University of Toronto will be initiated in December 2014 at the Maisonneuve-Rosemont … Continue reading

Comments Off on World Breakthrough: A New Molecule Allows for an Increase in Stem Cell Transplants

It’s Time to Learn About Fertility Treatment Options

Posted: Published on September 18th, 2014

Fair Oaks, VA (PRWEB) September 18, 2014 While it is estimated that at least one in eight couples is coping with infertility, it remains a topic that is not widely discussed leaving many people confused and unaware of the options available to them. Recognizing this information gap, Shady Grove Fertility is opening the doors of our offices in Fair Oaks, Virginia; Columbia, MD; and Harrisburg, PA throughout September for complimentary educational seminars. Stephen J. Greenhouse, M.D. in Fair Oaks, Joseph Osheroff, M.D. in Columbia, MD and Melissa A. Esposito, M.D. and Jason G. Bromer, M.D. in Harrisburg will join staff members to review the newest treatments, insurance options, and Shady Grove Fertilitys signature financial assistance programs. All attendees are eligible for a free new patient consultation with each physician. Taking the first step to seek information about infertility is often one of the most important," says Dr. Bromer in Harrisbug. "At Shady Grove Fertility we are committed to providing all the necessary education to help each patient at every stage. These seminars throughout the region are excellent ways to introduce our practice and help patients begin their journey towards having a baby." During the seminars the range of fertility treatments … Continue reading

Posted in IVF Treatment | Comments Off on It’s Time to Learn About Fertility Treatment Options

Human Genetics DNA and RNA.mp4 – Video

Posted: Published on September 18th, 2014

Human Genetics DNA and RNA.mp4 Table of Contents: 00:00 - Methylation and acetylation 01:30 - Who's in control? 01:32 - What is DNA and RNA? 02:45 - How do DNA and RNA differ? 03:56 - How ... By: Marc Reynolds … Continue reading

Posted in Human Genetics | Comments Off on Human Genetics DNA and RNA.mp4 – Video

Noir Genetics – Black Ops II Game Clip – Video

Posted: Published on September 18th, 2014

Noir Genetics - Black Ops II Game Clip Game Clip. By: 360CODBlackOps2 … Continue reading

Posted in Genetics | Comments Off on Noir Genetics – Black Ops II Game Clip – Video

Week 14-lecture 8-conservation genetics – Video

Posted: Published on September 18th, 2014

Week 14-lecture 8-conservation genetics Biol 252. By: hodana … Continue reading

Posted in Genetics | Comments Off on Week 14-lecture 8-conservation genetics – Video

New Editors Join G3: Genes|Genomes|Genetics, an Open Access Journal of the Genetics Society of America

Posted: Published on September 18th, 2014

Contact Information Available for logged-in reporters only Newswise The Genetics Society of America today announced new additions to the editorial board of its peer-reviewed, peer-edited journal G3: Genes|Genomes|Genetics. Since the journals launch in June 2011, its editorial board of academic experts has been instrumental in shaping G3 into an important forum for the publication of useful genetics findings and resources. As the breadth of research published in the journal continues to grow, Editor-in-Chief Brenda Andrews, PhD, has appointed two new Deputy Editors-in-Chief, who will contribute to the oversight of key sections: Also, Stephen Wright, PhD, University of Toronto, has been appointed as a new Senior Editor for Population and Evolutionary Genetics and Genomics and will spearhead the journals efforts to strengthen coverage of in this area. The new Deputy Editors-in-Chief and Senior Editor are joined by several new Associate Editor appointments to the editorial board this year: Genetics is a fast-paced field. The expanded editorial board will help us keep up with the growing volume and diversity of research being submitted to G3, said Brenda Andrews, G3: Genes|Genomes|Genetics Editor-in-Chief and Professor and Chair of the Banting & Best Department of Medical Research, University of Toronto. G3 was created by the … Continue reading

Posted in Genetics | Comments Off on New Editors Join G3: Genes|Genomes|Genetics, an Open Access Journal of the Genetics Society of America

Food manufacturers seek GMO labeling injunction

Posted: Published on September 18th, 2014

Products containing genetically modified ingredients would have to disclose that information on the back of the package near the nutritional facts under Vermont s bill. (Photo by John Herrick/VTDigger) BRATTLEBORO -- Contending Vermont's GMO labeling law is meant "to pacify a vocal segment of the population that opposes genetic engineering," the Grocery Manufacturers Association is asking a federal court to prevent the state from implementing Act 120 until its lawsuit against Vermont "has run its course." Act 120, which establishes labeling requirements for what it calls genetically engineered foods, was passed by the Legislature earlier this year and signed into law in May by Gov. Peter Shumlin. According to the motion for an injunction, because GE varieties of corn and soybean account for 90 percent of those types of plantings in the United States, Act 120 will affect most of the grocery products sold in Vermont. "Federal law does not require food labeling to also include plant labeling because there is no rational justification for such a regime," wrote attorneys for the GMA, the Snack Food Association, the International Dairy Association and the National Association of Manufacturers. "Act 120, however, is not concerned with rational justification. It caters to beliefs … Continue reading

Posted in Genetic Engineering | Comments Off on Food manufacturers seek GMO labeling injunction

Food manufacturers seek GMO labeling injuction

Posted: Published on September 18th, 2014

BRATTLEBORO -- Contending Vermont's GMO labeling law is meant "to pacify a vocal segment of the population that opposes genetic engineering," the Grocery Manufacturers Association is asking a federal court to prevent the state from implementing Act 120 until its lawsuit against Vermont "has run its course." Act 120, which establishes labeling requirements for what it calls genetically engineered foods, was passed by the Legislature earlier this year and signed into law in May by Gov. Peter Shumlin. According to the motion for an injunction, because GE varieties of corn and soybean account for 90 percent of those types of plantings in the United States, Act 120 will affect most of the grocery products sold in Vermont. "Federal law does not require food labeling to also include plant labeling because there is no rational justification for such a regime," wrote attorneys for the GMA, the Snack Food Association, the International Dairy Association and the National Association of Manufacturers. "Act 120, however, is not concerned with rational justification. It caters to beliefs and biases that a government has no business endorsing." Not only does Act 120 not serve any legitimate governmental interests, wrote the attorneys, it violates the First Amendment and … Continue reading

Posted in Genetic Engineering | Comments Off on Food manufacturers seek GMO labeling injuction

Page 3,599«..1020..3,5983,5993,6003,601..3,6103,620..»